- Split View
-
Views
-
Cite
Cite
Maria Manczak, Thimmappa S. Anekonda, Edward Henson, Byung S. Park, Joseph Quinn, P. Hemachandra Reddy, Mitochondria are a direct site of Aβ accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression, Human Molecular Genetics, Volume 15, Issue 9, 1 May 2006, Pages 1437–1449, https://doi.org/10.1093/hmg/ddl066
- Share Icon Share
Abstract
Alzheimer's disease (AD) is a complex, neurodegenerative disease characterized by the impairment of cognitive function in elderly individuals. In a recent global gene expression study of APP transgenic mice, we found elevated expression of mitochondrial genes, which we hypothesize represents a compensatory response because of mitochondrial oxidative damage caused by the over-expression of mutant APP and/or amyloid beta (Aβ). We investigated this hypothesis in a series of experiments examining what forms of APP and Aβ localize to the mitochondria, and whether the presence of these species is associated with mitochondrial dysfunction and oxidative damage. Using immunoblotting, digitonin fractionation, immunofluorescence, and electron microscopy techniques, we found a relationship between mutant APP derivatives and mitochondria in brain slices from Tg2576 mice and in mouse neuroblastoma cells expressing mutant human APP. Further, to determine the functional relationship between mutant APP/Aβ and oxidative damage, we quantified Aβ levels, hydrogen peroxide production, cytochrome oxidase activity and carbonyl proteins in Tg2576 mice and age-matched wild-type (WT) littermates. Hydrogen peroxide levels were found to be significantly increased in Tg2576 mice when compared with age-matched WT littermates and directly correlated with levels of soluble Aβ in Tg2576 mice, suggesting that soluble Aβ may be responsible for the production of hydrogen peroxide in AD progression in Tg2576 mice. Cytochrome c oxidase activity was found to be decreased in Tg2576 mice when compared with age-matched WT littermates, suggesting that mutant APP and soluble Aβ impair mitochondrial metabolism in AD development and progression. An increase in hydrogen peroxide and a decrease in cytochrome oxidase activity were found in young Tg2576 mice, prior to the appearance of Aβ plaques. These findings suggest that early mitochondrially targeted therapeutic interventions may be effective in delaying AD progression in elderly individuals and in treating AD patients.
INTRODUCTION
Alzheimer's Disease (AD) is a complex, heterogeneous and progressive dementia that is associated with neurofibrillary tangles and amyloid beta (Aβ) plaques (1–4). Neurofibrillary tangles and Aβ deposits have been found primarily in the regions of memory and cognition in AD patients and in AD transgenic mice. Since the discovery of the 4 kDa Aβ peptide—a cleaved product of amyloid precursor protein (APP) via sequential proteolysis of aspartyl beta secretase and presenilin-dependent secretase in AD brains—much research has focused on understanding Aβ toxicity and its relationship with AD progression and pathogenesis (5–7). It is now generally accepted that a progressive accumulation of Aβ aggregates eventually triggers a cascade of cellular changes, including mitochondrial oxidative damage, the hyperphosporylation of tau, synaptic failure and inflammation (8–18). However, initial triggers of mutant APP and/or intracellular Aβ are not clearly understood.
To understand the early and progressive cellular changes in AD development and progression, using cDNA microarray techniques, our laboratory recently investigated mRNA expressions in an AD transgenic mouse model (Tg2576) at three stages of disease progression: long before (2-months old), immediately before (5-months old) and after (18-months old), the appearance of amyloid pathology and cognitive impairment. A comparative gene expression analysis of Tg2576 mice and age-matched wild-type (WT) littermates (control) revealed that genes related to mitochondrial energy metabolism and apoptosis were up-regulated in the 2-, 5- and 18-month-old Tg2576 mice compared with the genes in WT littermates. These results suggest that, in the progression of AD, mitochondrial energy metabolism may be impaired by the expression of mutant APP, and/or soluble and insoluble Aβ (14).
The impairment of mitochondrial metabolism in AD patients has been well documented in the literature of AD (11–13,19–24). In addition, several in vitro studies of Aβ and mitochondrial function have reported that Aβ affects mitochondrial DNA and proteins, leading to impairments of the electronic transport chain (ETC) and ultimately mitochondrial dysfunction (9,10,23–31). Recently, Lustbader et al. (32) reported that Aβ-binding alcohol dehydrogenase directly interacts with Aβ in the mitochondria of AD patients and transgenic mice and that this interaction promotes the leakage of reactive oxygen species, ultimately leading to mitochondrial dysfunction. Markers of oxidative stress, including the oxidation of proteins, were found in AD brains (33). Further, the oxidation of DNA (9,10) and proteins (22,34) were found to be increased in Tg2576 mice compared with those in age-matched WT mice, suggesting that oxidative damage in the AD brain contributes to AD pathogenesis before Aβ accumulates (22,33,34). Evidence of abnormal mitochondrial gene expressions from our gene expression studies (14) suggests that mutant APP or Aβ may affect mitochondrial function, which, in turn, may generate reactive oxygen species, ultimately leading to oxidative damage in AD. If this hypothesized chain of events is confirmed, our gene expression data showing the up-regulation of mitochondrial genes may be interpreted as a compensatory response to mitochondrial dysfunction induced by mutant APP or Aβ (14). However, it is unclear how mitochondrial genes in Tg2576 mice are activated even before plaque formation—particularly in amyloid-rich regions of the Tg2576 mouse brain, and it is unclear whether Aβ is localized to mitochondria, whether this localization leads to impairment of the ETC, and whether, ultimately, these impairments induce free radicals. It is also unclear whether Aβ1–40 or Aβ1–42, or both, affect mitochondrial function.
To address these issues, in the present study, using biochemical and molecular methods, we studied the localization of Aβ in the mitochondria of Tg2576 mice and also in stably expressed mutant APP (Swe) in neuroblastoma (N2a) cell lines (35). We also measured soluble and insoluble Aβ1–40 and Aβ1–42 in the amyloid-rich region (the cerebral cortex) of 2-, 12- and 17-month-old Tg2576 mice. To determine whether Aβ1–40 and/or Aβ1–42 directly influences mitochondrial function, we measured hydrogen peroxide levels and cytochrome c oxidase activity in Tg2576 mice and in age-matched WT littermates (control). To determine the relationship between mutant APP, Aβ and oxidative damage, we used immunofluorescence methods to study 8-hydroxyguanosine (8-OHG; an oxidative damage marker) and Aβ immunoreactivity in the 2-, 8- and 17-month-old Tg2576 mice and age-matched WT littermates (control).
RESULTS
Evidence from Tg2576 mice: association between Aβ1–40, Aβ1–42 and mitochondria
To determine whether there is a relationship between Aβ and mitochondria, immunoblotting analysis was performed on isolated mitochondria from 6-month-old Tg2576 mice and age-matched WT mice. As shown in Figure 1, a 4 kDa Aβ monomer was detected only in the Tg2576 mice (lanes 3 and 4), and the 4 kDa band was completely absent in the WT mice, suggesting that 4 kDa Aβ is associated with mitochondria. To determine whether the 4 kDa Aβ is part of Aβ1–40 (the shorter form) or Aβ1–42 (the longer form), or both, we ran the mitochondrial protein lysates in a 4–20% gradient gel. As shown in Figure 2, a doublet of Aβ1–40 and Aβ1–42 bands were found in isolated mitochondria from the cortical tissues of the Tg2576 mice but not in the age-matched WT mice, suggesting that both Aβ1–40 and Aβ1–42 are associated with mitochondria.
To ensure the purity of the mitochondrial preparation from the cortical tissues of the Tg2576 and WT mice, we performed electron microscopy using mitochondrial pellets. As shown in Figure 3 and Supplementary Material, Figure S1, these mitochondrial preparations showed an enrichment of mitochondria (over 90%); rarely did we find lysosomes in the mitochondrial preparation.
Evidence from APP cell lines: oligomeric forms of Aβ are associated with mitochondria; Aβ is localized to the inner mitochondrial membrane
To confirm a relationship between Aβ and mitochondria, we studied Aβ and mitochondrial association in another system: mouse N2a cells stably expressing human mutant APP and human WT APP. This immunoblotting analysis showed 4 kDa Aβ in isolated mitochondria from mutant APP cell lines, but not in the mitochondrial pellet from WT APP cells, supporting the relationship between Aβ and mitochondria that we found in the Tg2576 mice (Fig. 4A). Further, to determine whether an oligomer formation of Aβ is also associated with mitochondria, we conducted immunoblotting analysis using an A11 antibody (which recognizes oligomers but not monomers) (36). As shown in Figure 4B, we found three distinct bands, ranging from 15 to 50 kDa of oligomers only in the mitochondrial pellet from the mutant APP cells, not in the mitochondrial pellet from the WT cells, suggesting that both monomers and oligomers of Aβ are associated with mitochondria.
To determine whether oligomer formation of Aβ is associated with a mitochondrial extract, we carried out immunoblotting analysis using (a) protein lysates from nuclear and mitochondrial extracts and (b) an A11-oligomer antibody that recognizes only oligomers. As shown in Figure 5, in mutant APP cell lines, we found oligomer formations mainly in the mitochondrial extract, less abundantly in the nuclear extract of mutant cells, and not in the nuclear extracts of cells expressing human WT APP. However, we found traces of oligomer formation in mitochondrial extracts of cells expressing human WT APP. These results demonstrated that both monomer and oligomers of Aβ are associated with mitochondria, suggesting that Aβ may likely localize to mitochondria and possibly cause mitochondrial dysfunction.
To determine whether Aβ is localized to mitochondria, in particular to the outer membrane or mitoplast (inner membrane plus matrix), we further dissected Aβ in association with mitochondria, using a digitonin-fractionation method (37) and immunoblotting analysis. Our immunoblotting analysis of digitonin-fractionated mitochondrial membranes revealed that most of the Aβ was in the mitoplast fraction and some was in the outer membrane of mitochondria, suggesting that Aβ enters mitochondria and localizes to mitoplast (Fig. 6). Further, using immunoblotting analyses of several antibodies specific to mitochondria, including Mn-SOD (matrix), COX IV and adenine nucleotide translocator (ANT; inner membrane), we further confirmed that Aβ is primarily localized to the mitoplast (inner membrane plus matrix). The immunoreactivity of Mn-SOD (matrix), COX IV and ANT were robust in lane 2 (Fig. 6) containing the mitoplast fraction and not in lane 3 (Fig. 6) containing the outer mitochondrial membrane fraction.
Intraneuronal Aβ and Aβ deposits in Tg2576 mice
To determine the time course of mutant APP expression and of Aβ formation, using immunohistochemical methods, we investigated cerebral cortex and hippocampus slices from 2-, 8- and 17-month-old Tg2576 mice. Our immunofluorescence analysis revealed no Aβ deposits in the 2-month-old Tg2576 mice, very few in the 8-month-old Tg2576 mice (data not shown) and an abundance in the 17-month-old Tg2576 mice (Fig. 8). As shown in Figure 8, we found intraneuronal Aβ in the 2-month-old Tg2576 mice, and the numbers progressively increased in an age-dependent manner to the 17-month-old Tg2576 mice. In addition, using ELISA, we also measured both soluble and insoluble Aβ levels in Tg2576 mice at three stages of disease progression (2-, 12- and 17-months old (Table 1). In the 2-month-old Tg2576 mice, we detected both soluble Aβ1–40 and Aβ1–42 intraneuronally, but no insoluble Aβ. In the 12-month-old Tg2576 mice, we found both soluble and insoluble Aβ, and in the 17-month-old Tg2576 mice, we found increased levels of both soluble and insoluble Aβ.
Immunofluorescence analysis of 8-OHG in Tg2576 mice and WT mice
To determine the time course of oxidative damage, using immunohistochemical methods, we investigated cerebral cortex slices from 2- and 17-month-old Tg2576 mice and age-matched WT littermates. Our immunofluorescence analysis of 8-OHG revealed increased immunoreactivity in 17-month-old Tg2576 mice compared with the immunoreactivity found in 2-month-old Tg2576 mice, suggesting that oxidative damage in Tg2576 mice is dependent on the accumulation of mutant APP derivatives, including intraneuronal Aβ. We also observed increased immunoreactivity in the 17-month-old WT mice when compared with the immunoreactivity found in the 2-month-old WT mice, suggesting that aging is responsible for increased oxidative damage in the 17-month-old WT mice.
Hydrogen peroxide levels in brain mitochondria from Tg2576 mice and WT mice
To determine whether mutant APP and Aβ induce free radicals in mitochondria, we measured hydrogen peroxide levels in isolated mitochondria from 2- and 17-month-old Tg2576 mice and age-matched WT littermates. Tissues were not available or sufficient for 12-month-old Tg2576 mice and age-matched WT littermates. We found increased levels of hydrogen peroxide in both 2-month-old (25% increase with P<0.01) and 17-month-old Tg2576 mice (12% increase, P=0.45) when compared with the age-matched WT mice. However, the levels were statistically significant only in the 2-month-old Tg2576 mice (P<0.01). We also observed an age-dependent increase of hydrogen peroxide in both the Tg2576 and WT mice (Table 2).
Carbonyl proteins in brain mitochondria from Tg2576 mice and WT mice
To determine whether Aβ alters carbonyl proteins in mitochondria, we measured carbonyl proteins in isolated mitochondria from 2- and 17-month-old Tg2576 mice and age-matched WT littermates. Tissues were not available or sufficient for 12-month-old Tg2576 mice and age-matched WT littermates. We found increased levels of carbonyl proteins in 2-month-old Tg2576 mice compared to the age-matched WT mice (20% increase, P=0.38), but not in the 17-month-old Tg2576 mice. We also noticed an age-dependent increase of carbonyl proteins in both the Tg2576 and WT mice (Table 2).
Correlation of Aβ production and hydrogen peroxide levels and carbonyl proteins in Tg2576 mice and WT mice
As shown in Table 3, both soluble Aβ1–40 and Aβ1–42 directly correlated with hydrogen peroxide levels but not insoluble Aβ1–40 and Aβ1–42 in Tg2576 mice. Among soluble Aβ, we found statistically significant correlations only for soluble Aβ1–40 (R=0.71 and P=0.02; Table 3 and Fig. 7).
Cytochrome c oxidase activity in brain mitochondria from Tg2576 mice and WT mice
We found decreased levels of cytochrome c oxidase in 2-month-old Tg2576 mice (20% decrease, P=0.58) compared with age-matched WT littermates. Tissues were not available or sufficient for 12-month-old Tg2576 mice and age-matched WT littermates (Table 2). However, we did not find a statistically significant decrease of cytochrome c oxidase activity in both the 2- and 17-month-old Tg2576 mice, compared with the age-matched WT mice (Table 2).
DISCUSSION
In the present study, using in vivo (Tg2576 mouse model) and in vitro (APP cell line), we found evidence demonstrating that both Aβ1–40 and Aβ1–42 are associated with brain mitochondria as the 4 kDa Aβ monomer (Figs 1 and 2). In addition to the 4 kDa Aβ monomer, we found that different sizes of oligomers are associated with mitochondria (Figs 4 and 5). Furthermore, our digitonin fractionation studies indicated that Aβ is more abundant in the mitoplast and less abundant in the outer membrane of mitochondria, suggesting that Aβ actually enters mitochondria (Fig. 6). These studies also suggest that Aβ interferes with mitochondrial function, with significantly increased hydrogen peroxide and carbonyls, and decreased cytochrome oxidase activity, particularly in the 2-month-old Tg2576 mice when compared with the age-matched WT littermates. The significant correlation found between hydrogen peroxide and soluble Aβ (P<0.01) also supported the hypothesis that Aβ promotes mitochondrial dysfunction and oxidative damage.
Aβ and mitochondria
Oxidative damage in association with mitochondrial dysfunction has been reported in the AD literature. In late-onset, sporadic AD, an age-dependent increase of reactive oxygen species has been identified as a key factor in the development and progression of AD (12,20,24). In familial AD, mitochondrial oxidative damage has also been overwhelmingly documented (20). However, the precise mechanistic link between mitochondrial oxidative damage and abnormal APP processing has not been elucidated. In a previous global gene expression study of Tg2576 mice, we investigated the gene expression profiles of transcripts at three stages of disease progression (compared with age-matched WT littermates): long before (2 months), immediately before (5 months) and after (18 months) the appearance of Aβ plaque pathology and cognitive impairment (14). This analysis revealed that the genes related to mitochondrial energy metabolism and apoptosis were up-regulated in the 2-month-old Tg2576 mice compared with the age-matched WT mice and that the same genes were also up-regulated in the 5- and 18-month-old Tg2576 mice. These results suggest that mitochondrial energy metabolism may be impaired by the expression of mutant APP and/or Aβ, and that the up-regulation of mitochondrial genes may be a compensatory response (14).
In the present study, we found Aβ1–40 and Aβ1–42 in the mitochondrial membranes in both Tg2576 mice and N2a cells expressing the mutant human APP. Our immunoblotting analyses of mitochondrial pellets from N2a cells expressing human mutant APP cells demonstrated the presence of Aβ oligomers in mitochondrial membranes. However, we also found oligomer immunoreactivity in N2a cells over-expressing human WT APP cells, suggesting a possibility of oligomer formation in the absence of human APP mutation. Using human postmortem brains, several biochemical and electron microscopy studies revealed that the oligomers were observed as robust in AD subjects and as less abundant in non-demented subjects (38,39), supporting our present findings of oligomer formation in N2a cells over-expressing human WT APP cells.
Further, our digitonin fractionation studies showed that Aβ was more abundant in the inner mitochondrial membrane and matrix fractions and less abundant in the outer mitochondrial membrane. These novel findings suggest that mutant APP derivatives enter the mitochondria and possibly disrupt the ETC, ultimately leading to oxidative damage. This hypothesis is supported by recent findings from Crouch et al. (29) and Caspersen et al. (40), in which Aβ was localized in the mitochondria. For the first time, our study demonstrated that both monomeric and oligomeric forms of Aβ are associated with mitochondria in Tg2576 mice and in N2a cells expressing the human mutant APP.
The findings from the present study also support our findings from our gene expression study of Tg2576 mice (14), in which we found abnormal mitochondrial gene expressions and oxidative damage in 2-month-old Tg2576 mice but in which we rarely observed intraneuronal Aβ at this early stage of disease progression.
Taken together, these findings suggest a possible link between mutant APP and mitochondria. Although researchers have not found direct evidence of such an association, a previous study by Anandatheerthavarada et al. (41) demonstrated that mutant APP accumulates in mitochondrial membranes in Tg2576 mice. They found that a chimeric N-terminal signal in the APP molecule enters mitochondria, via positively charged residues of APP molecule at 40, 44 and 51, and results in the import of APP into the mitochondria. However, because of the presence of an acidic domain spanning residue 220–229 of the APP transmembrane arrest form occurs with C-terminal region of APP facing the cytosol. Thus, the orientation of APP associated with mitochondrial membranes is the N-terminus in intra-mitochondrial space and the C-terminus towards the cytosol. Such early import of APP into mitochondria may disrupt the ETC in Tg2576 mice and lead to oxidative damage, possibly because this early import (at least before a Tg2576 mouse turns 2 months of age), and the subsequent impairment in mitochondrial ETC, may lead to mitochondrial dysfunction in the 2-month-old Tg2576 mice. To compensate for the loss of mitochondrial function caused by mutant APP, mitochondrial genes may be activated in the early stages of disease progression in Tg2576 mice (14).
The accumulation of Aβ in mitochondria may be explained by two possible mechanisms: (1) If full-length APP molecules enter mitochondria, then cleavage of 40–42 residues of APP (or the 4 kDa Aβ peptide) might occur in the mitochondria because γ secretase activity has been present in mitochondria, and γ secretase is required to facilitate cleavage of the APP molecule (42). Otherwise, we cannot explain the presence of the γ secretase complex in the mitochondria, which has been established (42). (2) The cleavage of the APP molecule (via the activation of the γ secretase and BACE, another enzyme required for cleavage of the APP molecule) may occur primarily in the cytoplasm and in the cleaved 40–42 residues of Aβ that are later transported to mitochondria, but there is no experimental evidence to support this second possibility. Findings from the present study and others (40,41) suggest for the possible mechanism: that mutant APP and its derivatives enter mitochondria and generate free radicals, ultimately leading to oxidative damage. Further research is needed to determine the precise mechanism resulting in the transport of Aβ into the mitochondria in AD neurons.
Mutant APP and Aβ induces free radicals and oxidative DNA damage
Our present investigation of hydrogen peroxide radicals clearly suggests a relationship between the accumulation of mutant APP derivatives (Aβ monomers and oligomers) and hydrogen peroxide production in the mitochondria of Tg2576 mice but not in age-matched WT littermates. We found increased hydrogen peroxide levels, carbonyl proteins and decreased cytochrome oxidase activity in 2-month-old Tg2576 mice when compared with their age-matched WT littermates. These findings support our original hypothesis that mutant APP derivatives enter the mitochondria in early stages of disease progression and induce free radicals, leading to mitochondrial oxidative damage. Our study mainly focused on measuring hydrogen peroxide radicals, carbonyl proteins and cytochrome oxidase activity in the mitochondria, because mitochondria are a major source of free radicals, and it has been proposed that Aβ induces free radicals in the mitochondria (20,22,32,40).
As discussed earlier, in addition to intraneuronal Aβ, it is possible that mutant APP also induces free radicals after mutant APP enters mitochondria. It is unlikely that mutant APP derivatives can induce hydrogen peroxide radicals without affecting the mitochondria (26). Our previous findings of abnormal mitochondrial gene expressions in 2-month-old Tg2576 mice (14), biochemical studies of APP imported to mitochondria (41) and the present findings of increased hydrogen peroxide production in Tg2576 mice suggest that APP-mediated free radicals may be responsible for mitochondrial oxidative damage in Tg2576 mice. Our findings of oxidative damage in Tg2576 mice are in agreement with previous studies of oxidative stress in Tg2576 mice (9,10,22,34,59). A correlative analysis between soluble Aβ1–40, soluble Aβ1–42, insoluble Aβ1–40, insoluble Aβ1–42 and hydrogen peroxide production in Tg2576 mice revealed that only soluble Aβ1–40 and soluble Aβ1–42 directly correlated with hydrogen peroxide production but insoluble Aβ1–40 and insoluble Aβ1–42 did not (Table 3 and Fig. 7), further strengthening support for our hypothesis that soluble Aβ enters mitochondria, induces free radicals and impairs mitochondrial metabolism in AD development and progression.
Findings from our immunofluorescence analysis of 8-OHG further support the presence of mitochondrial oxidative DNA damage in Tg2576 mice. We found DNA damage in 2-month-old Tg2576 mice and increases in DNA damage corresponding to the stages of disease development in Tg2576 mice (Fig. 9), suggesting that free radicals generated by mutant APP and its derivatives may likely be responsible for the mitochondrial oxidative DNA damage found in Tg2576 mice. However, to determine the precise connection between mitochondrial oxidative DNA damage and mutant APP derivatives in disease progression in Tg2576 mice from birth to death, quantitative methods such as HPLC are needed (43,44). Although apoptotic cell death has not been reported even in aged Tg2576 mice, mitochondrial oxidative DNA damage was evident in the study reported here and may be a key factor for synaptic dysfunction in Tg2576 mice.
It is now well established that mitochondrial oxidative DNA damage is a major factor in AD development and progression (9,11–14,45–48), and findings from this study and others support this hypothesis. In particular, using a comet assay, Migliore et al. (45) recently studied mitochondrial oxidative DNA damage in leukocytes in three subject groups: persons diagnosed with mild cognitive impairment (MCI), persons diagnosed with AD and healthy persons. Findings showed a significantly higher level of primary DNA damage in the leukocytes from the AD and the MCI subjects compared with the control subjects. Moreover, the amount of oxidized DNA bases (both purines and pyrimidines) was significantly higher in the MCI and AD subjects, compared with the amount of oxidized DNA bases in the control subjects, suggesting that oxidative stress, at least at the DNA level, may be an early event in the pathogenesis of AD (45). Such findings further support our results here. Further, in addition to DNA damage caused by mutant APP and Aβ that we observed, we also found increases in DNA damage corresponding to increases in the ages of the Tg2576 mice, supporting the widely accepted free-radical theory of aging in AD (21,22,44).
Our investigation here of carbonyl proteins showed that, in addition to mitochondrial oxidative DNA damage, increased oxidation of proteins occurred in 2-month-old Tg2576 mice. Although we did not find a statistically significant increase in carbonyl proteins in Tg2576 mice compared with the WT mice, our findings still indicate that proteins may gradually oxidize as the disease progresses. Further studies of carbonyl proteins in larger numbers of Tg2576 mice and age-matched WT littermates are needed to understand how Aβ is related to carbonyl proteins in the progression of AD. However, based on our study of carbonyl proteins, we suggest that oxidative damage may be an early event in AD progression. Oxidation of proteins is well documented in AD patients (49,50), and findings from this study support this observation.
Our investigation of Aβ production reported here revealed intraneuronal soluble Aβ in Tg2576 mice as young as 2-months old and that levels of both soluble and insoluble Aβ progressively increased in an age-dependent fashion (Table 1). The increase of soluble Aβ production significantly correlated with an increase of hydrogen peroxide radicals in Tg2576 mice. For other mitochondrial parameters, including carbonyl proteins and cytochrome c oxidase, we found a trend in which there was a decrease in cytochrome c oxidase and an increase in carbonyl proteins, but these values were not statistically significant in Tg2576 mice. There are several possibilities for not finding statistical significance (Table 2) and not finding positive correlations with Aβ production (Table 3): (1) the sample size may have been too small in this study, (2) Aβ itself may act as free radical scavenger and may reduce mitochondrial oxidative damage (51) and (3) to reduce mitochondrial toxicity caused by mutant APP derivatives, other neuroprotective genes may be activated as AD progresses in Tg2576 mice (14,52). These issues can be resolved by extending the present study with a larger number of mice at each of the three different stages of disease progression (2, 12 and 24 months) in Tg2576 mice and age-matched WT mice.
Even with the non-statistical significance of a few mitochondrial parameters (carbonyl proteins and cytochrome c oxidase), the present statistically significant findings of increased hydrogen peroxide (Tables 1–3 and Figs 7–9) suggest that soluble Aβ may be responsible for the generation of hydrogen peroxide radicals, oxidative DNA damage and the carbonyl proteins in Tg2576 mice. As discussed earlier, if mutant APP derivates enter mitochondria, impair ETC and cause oxidative damage to AD neurons, then mitochondrially targeted antioxidants may effectively decrease free radicals and oxidative damage, and may protect AD neurons from mutant APP derivates (53). Our findings point to the possible development of mitochondrial therapies for AD, particularly antioxidants that target mitochondria.
CONCLUSIONS
The mechanistic link between abnormal mitochondrial gene expression and oxidative damage in AD development and progression is unclear. In the present study, using immunoblotting, digitonin fractionation, immunofluorescence and electron microscopy techniques, we studied relationships between mitochondria and Aβ in Tg2576 mice and N2a cells expressing mutant human APP and WT human APP. We found an association between mutant APP derivatives (Aβ monomers and oligomers) and mitochondria in cerebral cortex slices from Tg2576 mice and N2a cells expressing mutant APP. Further, to determine the functional relationship between mutant APP, Aβ and oxidative damage, we studied Tg2576 mice and age-matched WT littermates, quantifying Aβ levels, hydrogen peroxide levels, cytochrome c oxidase activity and carbonyl proteins. We found intraneuronal Aβ levels in Tg2576 mice as young as 2-months old, and an age-dependent increase in both soluble and insoluble Aβ levels in 12- and 17-month-old Tg2576 mice. In addition, we found a significant increase in hydrogen peroxide levels in Tg2576 mice compared with the age-matched WT littermates. This increase directly correlated with levels of soluble Aβ in Tg2576 mice, suggesting that soluble Aβ may be responsible for the production of hydrogen peroxide in Tg2576 mice. We found cytochrome c oxidase activity decreased in 2-month-old Tg2576 mice compared with age-matched WT littermates. However, further investigation of large numbers of Tg2576 mice and age-matched WT littermates—from birth to death—is needed to determine the precise link between cytochrome oxidase activity and mitochondrial Aβ. Further, interpreting how findings such as those reported here using a Tg2576 mouse model apply to persons with AD is a major challenge to mitochondrial and AD researchers, one that will require a time course study of Aβ production, free radical production and oxidative damage in the Tg2576 model. However, at this stage of AD research, we can say that findings from transgenic mouse models, including those from this study, suggest that the mechanism of oxidative damage may also apply to AD humans: that mutant APP and soluble Aβ may enter mitochondria, induce free radicals and impair mitochondrial metabolism.
MATERIALS AND METHODS
Mice
The Tg2576 mice and age-matched WT littermates were housed at the Neurological Sciences Institute of Oregon Health and Science University (OHSU) and at the Veteran Affairs Medical Center in Portland. The mice were a gift from Dr Karen Hsiao, University of Minnesota (54). The OHSU Institutional Animal Care and Use Committee approved all procedures for animal care according to guidelines set forth by NIH.
Cell lines
We used mouse N2a cells expressing either mutant human APP or WT human APP. The mutant and WT cell lines were a gift from Drs Sangram Sisodia and Gopal Thinakarn, University of Chicago (35). They were grown in a medium containing a 1:1 mixture of DMEM/10%FBS and OptiMEM, supplemented with 0.4 mg/Ml G418 (Invitrogen, CA, USA). After 48 h, the cells were harvested and used for immunoblotting analysis of Aβ.
Preparation of Tg2576 mice tissues and APP cells, and isolation of mitochondrial proteins
For tissue preparation, brains from Tg2576 mice and age-matched WT littermates were harvested. The mice were sacrificed by cervical dislocation, the brains were removed and cerebral cortices were dissected. Mitochondria were isolated from the cortex as described in Caspersen et al. (40), with modifications. Briefly, mouse tissues and/or mutant APP and WT cell lines were homogenized using a Teflon-glass homogenizer in 1:10 weight/volume of an ice-cold homogenization buffer (0.5 g/ml pepstatin, 0.5 g/ml leupeptin, 1 mm PMSF, 1 mm EDTA, 250 mm sucrose, 1 mm EGTA and 10 mm HEPES/NAOH; Percoll–final concentration 14%; pH 7.4). The protein lysates were centrifuged at 1500g for 10 min, and a supernatant mitochondrial pellet was collected. The bottom pellet was used as the ‘nuclear pellet’ for our immunoblotting analysis. A homogenization buffer with Percoll was added again to the nuclear pellet and centrifuged for 15 min at 9000g to pellet pure mitochondria. The nuclear pellet was resuspended in a wash buffer (0.5 g/ml pepstatin 0.5 g/ml leupeptin, 1 mm PMSF, 250 mm sucrose, 1 mm EGTA, 1 mm EDTA and 10 mm Tris–HCl; pH 7.5) and centrifuged again. It was then resuspended in a wash buffer and stored at −80°C until the protein assay was performed. The concentration of mitochondrial proteins in each sample was determined using the BCA method (Pierce Biotechnology, Rockford, IL, USA).
Immunoblotting analysis of mitochondrial pellets from Tg2576 mice and APP cell lines
To detect the 4 kDa Aβ peptide in the mitochondrial pellet, 10 µg of the mitochondrial protein, which was prepared from Tg2576 and WT mice brain specimen and/or from APP and WT cell lines, was resolved on a 10–20% gradient gel (Tricine–SDS). To differentiate Aβ1–40 and Aβ1–42 residues in the mitochondrial pellet, a 4–20% gradient gel (Tricine–SDS) was used. The resolved protein was transferred to nylon membranes (Novax Inc., San Diego, CA, USA) that were then incubated at room temperature with a blocking buffer (5% dry milk dissolved in a TBST buffer) for 1 h. The nylon membranes were incubated with the primary antibodies Aβ1–40 (with a dilution of 1:100) and Aβ1–42 (1:100) (polyclonal rabbit) (Chemicon International, CA, USA), voltage-dependent anion channel (VDAC) (1:1500) and COX IV (1:1000) (monoclonal) (Molecular Probes, Eugene, OR, USA). The membranes were washed with a TBST buffer three times at 10 min intervals and then incubated with appropriate secondary antibodies for 2 h, followed by washing again three times with a TBST buffer. Protein expression was detected with chemiluminescent reagents (Pierce Biotechnology).
To determine whether oligomer formation of Aβ is associated with a mitochondrial fraction, both the nuclear and the mitochondrial pellets were resolved on a 10–20% gradient gel (Tricine–SDS). Immunoblotting analysis was performed using the A11-oligomer (polyclonal rabbit) antibody (1:1000) (Biosource International, CA, USA) that recognized only the oligomers (36) in our immunoblots.
Preparation of digitonin mitochondrial fractions and immunoblotting analysis
To separate mitochondrial membranes (outer, inner and matrix) from themitochondrial pellet prepared from APP cell lines, a digitonin fractionation method was used, following Schnaitman and Greenwalt (37). Briefly, a 2% digitonin stock solution was prepared. The BSA and digitonin were added to an ice-cold homogenization buffer (0.5 g/ml pepstatin, 0.5 g/ml leupeptin, 1 mm PMSF, 1 mm EDTA, 250 mm sucrose, 1 mm EGTA and 10 mm HEPES/NAOH; pH 7.4). An aliquot of the ice-cold buffer was added to the mitochondrial pellet through continuous stirring. The diluted suspension was homogenized gently by hand and centrifuged at 12 000g. The supernatant was carefully drawn off, and the pellet was gently resuspended in the isolation buffer. This suspension was centrifuged again at the same speed for 10 min. The pellet from the second centrifugation was designated as the ‘low-speed pellet’ or the ‘inner-membrane plus matrix’. The supernatants from the first and second centrifugation were pooled and were designated as the ‘low-speed supernatant’. The low-speed supernatant was fractionated at 144 000g for 1 h. The pellet from this centrifugation was designated as the ‘high-speed pellet’ or the ‘outer membrane’. These low-speed and high-speed pellets were resolved in a 12% SDS-PAGE gel and used for immunoblotting analysis with Aβ1–40 (1:100) (polyclonal rabbit) (Chemicon International), and for analyses of mitochondrial antibodies COX IV (1:1000), ANT (1:1000) (inner membrane) (Molecular Probes), Mn-SOD (1:200) (matrix) (Sigma–Aldrich) and VDAC (1:1500) (outer membrane) (Molecular Probes).
Electron microscopy of the mitochondrial pellet
The isolated mitochondria from the Tg2576 mice and WT mice were fixed in a Karnovsky's fixative for 1 h and then rinsed in a 0.1 m sodium cacodylate buffer. They were post-fixed in 1% osmium tetroxide for 1 h, rinsed in water, dehydrated in a graded series of acetone and then infiltrated overnight in half acetone and half epon resin. The tissue was fixed in Epon 812 at 60°C for 12 h. The embedded blocks were sectioned on a Leica ultramicrotome. The sections were mounted on 300 mesh grids, stained with lead citrate and uranyl acetate, and viewed on a FEI Morgagni electron microscope. Images were captured with a 2K digital camera.
Measurement of hydrogen peroxide in isolated mitochondria
The production of hydrogen peroxide in the cortical mitochondria of Tg2576 mice and age-matched WT littermates was measured using an Amplex® Red Hydrogen Peroxide Assay Kit (A22188) (Molecular Probes). A BCA™ Protein Assay Kit (Pierce Biotechnology) was used to estimate the total mitochondrial proteins. The working reaction mixture contained the mitochondrial proteins (µg/µl), Amplex Red reagents (50 µm), horseradish peroxidase (HRP) (0.1 U/ml) and a reaction buffer (1X). The mixture was incubated at room temperature for 30 min before spectrophotometer readings were taken at 570 nm. Finally, hydrogen peroxide production was determined using a standard curve equation and were expressed in nmol/µg mitochondrial protein.
Measurement of cytochrome c oxidase activity in isolated mitochondria
Cytochrome c oxidase activity was measured in an isolated mitochondrial pellet. Enzyme activity was assayed spectrophotometrically using a Sigma Kit (Sigma–Aldrich) following manufacturer's instructions. Briefly, 2 µg of mitochondrial protein was added to 1.1 ml of the reaction solution, which contained 50 µl of 0.22 mm ferricytochrome c fully reduced by sodium hydrosulphide, Tris–HCl (pH 7.0) and 120 mm potassium chloride. The decrease of absorbance at 550 mm was recorded for a 1-min reaction at 10-s intervals, and cytochrome c oxidase activity of cytochrome oxidase was measured according to the following formula: mU/mg of total mitochondrial protein = (ΔA/min sample − (ΔA/min blank) × 1.1 mg protein × 21.84). The protein concentrations were determined following the BCA method.
Measurement of carbonyl proteins in isolated mitochondria
Carbonyl proteins in the cortical mitochondria of Tg2576 mice and age-matched WT littermates were determined with the Zentech PC Test (Protein Carbonyl Enzyme Immuno-Assay Kit; Biocell Corporation Ltd). Briefly, the mitochondrial samples (5 µl) were allowed to react with a dinitrophenylhydrazine (DNP) solution (200 µl). The DNP-reacted proteins bound non-specifically to an ELISA plate, and the unconjugated DNP and non-protein entities were washed away. The adsorbed DNP–protein was then probed with an anti-DNP-biotin antibody, followed by a streptavidin-linked HRP probe. Then the chromatin reagent that contained peroxide was added to catalyze the oxidation of TMB. Finally, the reaction was stopped by the addition of a stopping reagent (acid, provided with the kit), and the absorbance was measured for each well at 450 nm using a spectrophotometer. Along with controls and samples, protein carbonyl standards were also included in the assay. The content of the carbonyl protein in the mitochondrial samples was determined as pmol/mg protein, using the standard curve.
Measurement of soluble and insoluble Aβ levels inTg2576 mice and WT mice
The cerebral cortex from the right half of each mouse brain was snap-frozen on dry ice at the time of sacrifice and stored at −70°C until a homogenate was prepared according to Lim et al. (55) and Stackman et al. (56). Briefly, samples were homogenized in a Tris-buffered saline (pH 8.0) containing protease inhibitors (20 mg/ml pepstatin A, aprotinin, phophsoramidon and leupeptin; 0.5 mm PMSF; and 1 mm EGTA). Samples were sonicated briefly and centrifuged at 10 000g for 20 min at 4°C. The soluble fraction was used to determine the soluble Aβ by ELISA. To measure the insoluble Aβ, the pellet was re-suspended in 70% formic acid and again centrifuged. The extract was neutralized with 0.25 m Tris (pH 8.0) containing 30% acetonitrile and 5 m NaOH before we used ELISA to determine the insoluble Aβ. For each sample, Aβ1–40 and Aβ1–42 were measured using commercial colorimetric ELISA kits (Biosource International) specific for each species. A 96-well plate washer and reader were used, following the manufacturer's instructions. Each sample was run in duplicate. The protein concentrations of the homogenates were determined by the BSA method, and Aβ was expressed as pg Aβ/mg protein.
Immunofluorescence analysis of oxidative damage in Tg2576 mice and WT mice
To determine whether oxidative damage occurs early in AD progression, we studied 8-OHG in brain specimens from 2-month-old (n=5), 8-month-old (n=5) and 17-month-old Tg2576 mice (n=5); and from 2-month-old (n=5), 8-month-old (n=5) and 18-month-old WT mice (n=5). Immunofluorescence was carried out following Reddy et al. (14) and Manczak et al. (44). The sections were blocked with a buffer solution (0.5% Triton in PBS +10% rabbit serum +1% BSA) and then incubated overnight at room temperature with a goat anti-8-OHG, polyclonal antibody (1:50 dilution) (Alpha Diagnostics, San Antonio, TX, USA). On the day after primary antibody incubation, the sections were washed with a washing buffer (0.5% Triton in PBS). For 8-OHG, the sections were incubated with a secondary biotinylated anti-mouse antibody at a dilution of 1:2000 (Vector Laboratories, Burlingame, CA, USA) for 1 h at room temperature. The sections were then washed with PBS (pH 7.4) three times for 10 min each and were blocked for 1 h with a 1% blocking buffer (Molecular Probes). They were subsequently incubated with a streptavidin HRP solution for 1 h (Molecular Probes) and then washed with PBS (pH 7.4) three times for 10 min each. The sections were treated with the fluorescent dye Alexa 488 (green) (Molecular Probes) for 10 min at room temperature and counter-stained with Hoechst (1:1000) (blue) for nuclear labeling. Photographs were taken with a multiphoton laser scanning microscope system (Zeiss Meta LSM510).
Immunofluorescence analysis of intraneuronal Aβ and Aβ deposits in Tg2576 mice
We used immunofluorescence analysis to determine the expression of intraneuronal Aβ and Aβ deposits in Tg2576 mice in 2, 8- and 17-month-old Tg2576 mice, following Reddy et al. (14) and Manczak et al. (44). Briefly, the brain sections were fixed in 4% paraformaldehyde and incubated overnight at room temperature, with rabbit anti-Aβ1–42 polyclonal antibody in a 1:100 dilution (Chemicon International). On the next day, the sections were incubated with the secondary antibody anti-mouse HRP in a 1:200 dilution for 1 h. Then the slides were incubated with the tyramide-tagged fluorescent dye Alexa 594 (red) (Molecular Probes) for 10 min at room temperature. Photographs were taken with a multiphoton laser scanning microscope system (Zeiss Meta LSM510).
Statistical analysis
Descriptive statistical analysis was carried out for Aβ production (only in Tg2576 mice), hydrogen peroxide, carbonyl proteins and cytochrome c oxidase activity in Tg2576 mice and age-matched WT littermates. To determine relationships between Aβ production and hydrogen peroxide levels, and Aβ production and carbonyl proteins, if any, we conducted correlation analyses.
SUPPLEMENTARY MATERIAL
Supplementary material is available at HMG Online.
ACKNOWLEDGEMENTS
The authors thank Sandra Oster, OHSU Neurological Sciences Institute, for critical reading of the manuscript. This research was supported in part by the American Federation for Aging Research (to P.H.R.), the U.S. Department of Veteran's Affairs Advanced Research Career Development Award and NIH-AT0006 (to J.Q.) and NCRR grant no. RR016858.
Conflict of Interest statement. Authors declare that they have no conflict of interest regarding this manuscript.
. | Number of Tg2576 mice . | Sol Aβ1–40 Mean±SE (pg Aβ/mg protein) . | Insol Aβ1–40 Mean±SE (pg Aβ/mg protein) . | Sol Aβ1–42 Mean±SE (pg Aβ/mg protein) . | Insol Aβ1–42 Mean±SE (pg Aβ/mg protein) . |
---|---|---|---|---|---|
2-month-old | 5 | 1.38±0.24 | 0.20±0.08 | 3.16±1.44 | |
12-month-old | 5 | 11.51±5.21 | 62.57±17.68 | 4.77±2.33 | 38.78±4.97 |
17-month-old | 8 | 81.08±4.90 | 26005.61±2391.14 | 6.60±0.44 | 4465.46±383.45 |
Ratios | Sol Aβ 1–40/1–42 | Insol Aβ 1–40/1–42 | |||
2-month-old | 3.30±0.87 | ||||
12-month-old | 4.47±2.42 | 1.51±0.23 | |||
17-month-old | 12.64±1.15 | 5.90±0.41 |
. | Number of Tg2576 mice . | Sol Aβ1–40 Mean±SE (pg Aβ/mg protein) . | Insol Aβ1–40 Mean±SE (pg Aβ/mg protein) . | Sol Aβ1–42 Mean±SE (pg Aβ/mg protein) . | Insol Aβ1–42 Mean±SE (pg Aβ/mg protein) . |
---|---|---|---|---|---|
2-month-old | 5 | 1.38±0.24 | 0.20±0.08 | 3.16±1.44 | |
12-month-old | 5 | 11.51±5.21 | 62.57±17.68 | 4.77±2.33 | 38.78±4.97 |
17-month-old | 8 | 81.08±4.90 | 26005.61±2391.14 | 6.60±0.44 | 4465.46±383.45 |
Ratios | Sol Aβ 1–40/1–42 | Insol Aβ 1–40/1–42 | |||
2-month-old | 3.30±0.87 | ||||
12-month-old | 4.47±2.42 | 1.51±0.23 | |||
17-month-old | 12.64±1.15 | 5.90±0.41 |
. | Number of Tg2576 mice . | Sol Aβ1–40 Mean±SE (pg Aβ/mg protein) . | Insol Aβ1–40 Mean±SE (pg Aβ/mg protein) . | Sol Aβ1–42 Mean±SE (pg Aβ/mg protein) . | Insol Aβ1–42 Mean±SE (pg Aβ/mg protein) . |
---|---|---|---|---|---|
2-month-old | 5 | 1.38±0.24 | 0.20±0.08 | 3.16±1.44 | |
12-month-old | 5 | 11.51±5.21 | 62.57±17.68 | 4.77±2.33 | 38.78±4.97 |
17-month-old | 8 | 81.08±4.90 | 26005.61±2391.14 | 6.60±0.44 | 4465.46±383.45 |
Ratios | Sol Aβ 1–40/1–42 | Insol Aβ 1–40/1–42 | |||
2-month-old | 3.30±0.87 | ||||
12-month-old | 4.47±2.42 | 1.51±0.23 | |||
17-month-old | 12.64±1.15 | 5.90±0.41 |
. | Number of Tg2576 mice . | Sol Aβ1–40 Mean±SE (pg Aβ/mg protein) . | Insol Aβ1–40 Mean±SE (pg Aβ/mg protein) . | Sol Aβ1–42 Mean±SE (pg Aβ/mg protein) . | Insol Aβ1–42 Mean±SE (pg Aβ/mg protein) . |
---|---|---|---|---|---|
2-month-old | 5 | 1.38±0.24 | 0.20±0.08 | 3.16±1.44 | |
12-month-old | 5 | 11.51±5.21 | 62.57±17.68 | 4.77±2.33 | 38.78±4.97 |
17-month-old | 8 | 81.08±4.90 | 26005.61±2391.14 | 6.60±0.44 | 4465.46±383.45 |
Ratios | Sol Aβ 1–40/1–42 | Insol Aβ 1–40/1–42 | |||
2-month-old | 3.30±0.87 | ||||
12-month-old | 4.47±2.42 | 1.51±0.23 | |||
17-month-old | 12.64±1.15 | 5.90±0.41 |
. | Mice studied . | Hydrogen peroxide levels Mean±SE Difference/trend (nmol/mg mitochondrial protein) . | Carbonyl proteins Mean±SE Difference/trend (pmol/mg mitochondrial protein) . | Cytochrome oxidase activity Mean±SE Difference/trend (mU/mg mitochondrial protein) . | ||||
---|---|---|---|---|---|---|---|---|
2-month-old Tg2576 mice | 5 | 5063.60±626.36 | 1:0.75=25% increase in Tg2576 mice (P<0.01)a | 189.20±19.76 | 1:0.8=20% increase in Tg2576 mice (P=0.38) | 0.13±0.03 | 1:1.2=20% decrease in Tg2576 mice (P=0.58) | |
2-month-old WT mice | 5 | 3810.93±619.41 | 152.75±17.00 | 0.16±0.03 | ||||
17-month-old Tg2576 mice | 5 | 7519.00±958.83 | 1:0.88=12% increase in Tg2576 mice (P=0.45). | 189.40±18.26 | 1:1.07= No change | 1.09±0.17 | 1:0.77=23% increase in Tg2576 mice | |
17-month-old WT mice | 5 | 6621.38±613.88 | 202.50±23.64 | 0.84±0.09 |
. | Mice studied . | Hydrogen peroxide levels Mean±SE Difference/trend (nmol/mg mitochondrial protein) . | Carbonyl proteins Mean±SE Difference/trend (pmol/mg mitochondrial protein) . | Cytochrome oxidase activity Mean±SE Difference/trend (mU/mg mitochondrial protein) . | ||||
---|---|---|---|---|---|---|---|---|
2-month-old Tg2576 mice | 5 | 5063.60±626.36 | 1:0.75=25% increase in Tg2576 mice (P<0.01)a | 189.20±19.76 | 1:0.8=20% increase in Tg2576 mice (P=0.38) | 0.13±0.03 | 1:1.2=20% decrease in Tg2576 mice (P=0.58) | |
2-month-old WT mice | 5 | 3810.93±619.41 | 152.75±17.00 | 0.16±0.03 | ||||
17-month-old Tg2576 mice | 5 | 7519.00±958.83 | 1:0.88=12% increase in Tg2576 mice (P=0.45). | 189.40±18.26 | 1:1.07= No change | 1.09±0.17 | 1:0.77=23% increase in Tg2576 mice | |
17-month-old WT mice | 5 | 6621.38±613.88 | 202.50±23.64 | 0.84±0.09 |
aStatistically significant.
. | Mice studied . | Hydrogen peroxide levels Mean±SE Difference/trend (nmol/mg mitochondrial protein) . | Carbonyl proteins Mean±SE Difference/trend (pmol/mg mitochondrial protein) . | Cytochrome oxidase activity Mean±SE Difference/trend (mU/mg mitochondrial protein) . | ||||
---|---|---|---|---|---|---|---|---|
2-month-old Tg2576 mice | 5 | 5063.60±626.36 | 1:0.75=25% increase in Tg2576 mice (P<0.01)a | 189.20±19.76 | 1:0.8=20% increase in Tg2576 mice (P=0.38) | 0.13±0.03 | 1:1.2=20% decrease in Tg2576 mice (P=0.58) | |
2-month-old WT mice | 5 | 3810.93±619.41 | 152.75±17.00 | 0.16±0.03 | ||||
17-month-old Tg2576 mice | 5 | 7519.00±958.83 | 1:0.88=12% increase in Tg2576 mice (P=0.45). | 189.40±18.26 | 1:1.07= No change | 1.09±0.17 | 1:0.77=23% increase in Tg2576 mice | |
17-month-old WT mice | 5 | 6621.38±613.88 | 202.50±23.64 | 0.84±0.09 |
. | Mice studied . | Hydrogen peroxide levels Mean±SE Difference/trend (nmol/mg mitochondrial protein) . | Carbonyl proteins Mean±SE Difference/trend (pmol/mg mitochondrial protein) . | Cytochrome oxidase activity Mean±SE Difference/trend (mU/mg mitochondrial protein) . | ||||
---|---|---|---|---|---|---|---|---|
2-month-old Tg2576 mice | 5 | 5063.60±626.36 | 1:0.75=25% increase in Tg2576 mice (P<0.01)a | 189.20±19.76 | 1:0.8=20% increase in Tg2576 mice (P=0.38) | 0.13±0.03 | 1:1.2=20% decrease in Tg2576 mice (P=0.58) | |
2-month-old WT mice | 5 | 3810.93±619.41 | 152.75±17.00 | 0.16±0.03 | ||||
17-month-old Tg2576 mice | 5 | 7519.00±958.83 | 1:0.88=12% increase in Tg2576 mice (P=0.45). | 189.40±18.26 | 1:1.07= No change | 1.09±0.17 | 1:0.77=23% increase in Tg2576 mice | |
17-month-old WT mice | 5 | 6621.38±613.88 | 202.50±23.64 | 0.84±0.09 |
aStatistically significant.
. | Sol Aβ1–40 . | Sol Aβ1–42 . | Insol Aβ1–40 . | Insol Aβ1–42 . |
---|---|---|---|---|
Hydrogen peroxide | ||||
R | 0.71 | 0.41 | −0.09 | 0.42 |
P | 0.02a | 0.31 | 0.89 | 0.29 |
Number of mice | 10 | 10 | 5 | 8 |
Carbonyl proteins | ||||
R | 0.1039 | −0.14 | 0.67 | 0.14 |
P | 0.78 | 0.75 | 0.23 | 0.74 |
Number of mice | 10 | 10 | 5 | 8 |
. | Sol Aβ1–40 . | Sol Aβ1–42 . | Insol Aβ1–40 . | Insol Aβ1–42 . |
---|---|---|---|---|
Hydrogen peroxide | ||||
R | 0.71 | 0.41 | −0.09 | 0.42 |
P | 0.02a | 0.31 | 0.89 | 0.29 |
Number of mice | 10 | 10 | 5 | 8 |
Carbonyl proteins | ||||
R | 0.1039 | −0.14 | 0.67 | 0.14 |
P | 0.78 | 0.75 | 0.23 | 0.74 |
Number of mice | 10 | 10 | 5 | 8 |
aStatistically significant.
. | Sol Aβ1–40 . | Sol Aβ1–42 . | Insol Aβ1–40 . | Insol Aβ1–42 . |
---|---|---|---|---|
Hydrogen peroxide | ||||
R | 0.71 | 0.41 | −0.09 | 0.42 |
P | 0.02a | 0.31 | 0.89 | 0.29 |
Number of mice | 10 | 10 | 5 | 8 |
Carbonyl proteins | ||||
R | 0.1039 | −0.14 | 0.67 | 0.14 |
P | 0.78 | 0.75 | 0.23 | 0.74 |
Number of mice | 10 | 10 | 5 | 8 |
. | Sol Aβ1–40 . | Sol Aβ1–42 . | Insol Aβ1–40 . | Insol Aβ1–42 . |
---|---|---|---|---|
Hydrogen peroxide | ||||
R | 0.71 | 0.41 | −0.09 | 0.42 |
P | 0.02a | 0.31 | 0.89 | 0.29 |
Number of mice | 10 | 10 | 5 | 8 |
Carbonyl proteins | ||||
R | 0.1039 | −0.14 | 0.67 | 0.14 |
P | 0.78 | 0.75 | 0.23 | 0.74 |
Number of mice | 10 | 10 | 5 | 8 |
aStatistically significant.
References
Tanzi, R.E. and Bertram, L. (
Reddy, P.H. and McWeeney, S. (
Walsh, D.M., Klyubin, I., Fadeeva, J.V., Cullen, W.K., Anwyl, R., Wolfe, M.S., Rowan, M.J. and Selkoe, D.J. (
Hardy, J. and Selkoe, D.J. (
Sisodia, S.S., Annaert, W., Kim, S.H. and De Strooper, B. (
Pappolla, M.A., Omar, R.A., Kim, K.S. and Robakis, N.K. (
Bozner, P., Grishko, V., LeDoux, S.P., Wilson, G.L., Chyan, Y.C. and Pappolla, M.A. (
Pappolla, M.A., Chyan, Y.J., Omar, R.A., Hsiao, K., Perry, G., Smith, M.A. and Bozner, P. (
Hirai, K., Aliev, G., Nunomura, A., Fujioka, H., Russell, R.L., Atwood, C.S., Johnson, A.B., Kress, Y., Vinters, H.V., Tabaton, M. et al. (
Swerdlow, R.H. and Khan, S.M. (
Manczak, M., Park, B.S., Jung, Y. and Reddy, P.H. (
Reddy, P.H., McWeeney, S., Park, B.S., Manczak, M., Gutala, R.V., Partovi, D., Jung, Y., Yau, V., Searles, R., Mori, M. and Quinn, J. (
Reddy, P.H., Mani, G., Park, B.S., Jacques, J., Murdoch, G., Whetsell, W., Jr., Kaye, J. and Manczak, M. (
Kitazawa, M., Oddo, S., Yamasaki, T.R., Green, K.N. and LaFerla, F.M. (
Tanzi, R.E. (
Oddo, S., Caccamo, A., Tran, L., Lambert, M.P., Glabe, C.G., Klein, W.L. and Laferla, F.M. (
Butterfield, D.A., Drake, J., Pocernich, C. and Castegna, A. (
Reddy, P.H. and Beal, M.F. (
Beal, M.F. (
Reddy, P.H. (
Swerdlow, R.H., Parks, J.K., Cassarino, D.S., Maguire, D.J., Maguire, R.S., Bennett, J.P., Jr., Davis, R.E. and Parker, W.D., Jr. (
Khan, S.M., Cassarino, D.S., Abramova, N.N., Keeney, P.M., Borland, M.K., Trimmer, P.A., Krebs, C.T., Bennett, J.C., Parks, J.K., Swerdlow, R.H., Parker, W.D., Jr. and Bennett, J.P., Jr. (
Casley, C.S., Canevari, L., Land, J.M., Clark, J.B. and Sharpe, M.A. (
Cardoso, S.M., Santos, S., Swerdlow, R.H. and Oliveira, C.R. (
Cardoso, S.M., Santana, I., Swerdlow, R.H. and Oliveira, C.R. (
Keil, U., Bonert, A., Marques, C.A., Scherping, I., Weyermann, J., Strosznajder, J.B., Muller-Spahn, F., Haass, C., Czech, C., Pradier, L., Muller, W.E. and Eckert, A. (
Crouch, P.J., Blake, R., Duce, J.A., Ciccotosto, G.D., Li, Q.X., Barnham, K.J., Curtain, C.C., Cherny, R.A., Cappai, R., Dyrks, T., Masters, C.L. and Trounce, I.A. (
Aleardi, A.M., Benard, G., Augereau, O., Malgat, M., Talbot, J.C., Mazat, J.P., Letellier, T., Dachary-Prigent, J., Solaini, G.C. and Rossignol, R. (
Abdul, H.M., Sultana, R., Keller, J.N., Clair, D.K.S., Markesbery, W.R. and Butterfield, D.A. (
Lustbader, J.W., Cirilli, M., Lin, C., Xu, H.W., Takuma, K., Wang, N., Caspersen, C., Chen, X., Pollak, S., Chaney, M. et al. (
Smith, M.A., Perry, G., Richey, P.L., Sayre, L.M., Anderson, V.E., Beal, M.F. and Kowall, N. (
Pratico, D., Uryu, K., Leight, S., Trojanoswki, J.Q. and Lee, V.M. (
Thinakaran, G., Teplow, D.B., Siman, R., Greenberg, B. and Sisodia, S.S. (
Kayed, R., Head, E., Thompson, J.L., McIntire, T.M., Milton, S.C., Cotman, C.W. and Glabe, C.G. (
Schnaitman, C. and Greenawalt, J.W. (
Kuo, Y.M., Emmerling, M.R., Vigo-Pelfrey, C., Kasunic, T.C., Kirkpatrick, J.B., Murdoch, G.H., Ball, M.J. and Roher, A.E. (
Kokubo, H., Kayed, R., Glabe, C.G. and Yamaguchi, H. (
Caspersen, C., Wang, N., Yao, J., Sosunov, A., Chen, X., Lustbader, J.W., Xu, H.W., Stern, D., McKhann, G. and Yan, S.D. (
Anandatheerthavarada, H.K., Biswas, G., Robin, M.A. and Avadhani, N.G. (
Hansson, C.A., Frykman, S., Farmery, M.R., Tjernberg, L.O., Nilsberth, C., Pursglove, S.E., Ito, A., Winblad, B., Cowburn, R.F., Thyberg, J. and Ankarcrona, M. (
Helbock, H.J., Beckman, K.B., Shigenaga, M.K., Walter, P.B., Woodall, A.A., Yeo, H.C. and Ames, B.N. (
Manczak, M., Jung, Y., Park, B.S., Partovi, D. and Reddy, P.H. (
Migliore, L., Fontana, I., Colognato, R., Coppede, F., Siciliano, G. and Murri, L. (
Pratico, D. (
Gibson, G.E. and Huang, H.M. (
Beal, M.F. (
Korolainen, M.A., Goldsteins, G., Nyman, T.A., Alafuzoff, I., Koistinaho, J. and Pirttila, T. (
Boyd-Kimball, D., Castegna, A., Sultana, R., Poon, H.F., Petroze, R., Lynn, B.C., Klein, J.B. and Butterfield, D.A. (
Bush, A.I., Atwood, C.S., Goldstein, L.E., Huang, X. and Rogers, J. (
Stein, T.D. and Johnson, J.A. (
Reddy, P.H. Mitochondrial oxidative damage in Aging and Alzheimer's Disease: implications to mitochondrially targeted antioxidants.
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F. and Cole, G. (
Lim, G.P., Chu, T., Yang, F., Beech, W., Frautschy, S.A. and Cole, G.M. (
Stackman, R.W., Eckenstein, F., Frei, B., Kulhanek, D., Nowlin, J. and Quinn, J.F. (
Bijur, G.N. and Jope, R.S. (
McEnery, M.W., Dawson, T.M., Verma, A., Gurley, D., Colombini, M. and Snyder, S.H. (